title: Two-stage hepatectomy for multiple bilobar colorectal liver metastases.
abstract: BACKGROUND
  As surgical resection of colorectal liver metastases (CLM) remains the only treatment for cure, efforts to extend the surgical indications to include patients with multiple bilobar CLM have been made. This study evaluated the long-term outcome, safety and efficacy of two-stage hepatectomy (TSH) for CLM in a large cohort of patients.
  
  
  METHODS
  Patients undergoing surgery between December 1996 and December 2009 were reviewed. The early postoperative and long-term outcomes as well as the patterns of failure to complete TSH and its clinical implications were analysed.
  
  
  RESULTS
  Eighty patients were scheduled to undergo TSH. Sixty-one patients had completion of TSH combined with (58 patients), or without (3) portal vein embolization/ligation (PVE/PVL). Five patients were excluded after first-stage hepatectomy and 14 after PVE/PVL. The 5-year overall survival rate and median survival in patients who completed TSH were 32 per cent and 39·6 months respectively, and corresponding recurrence-free values were 11 per cent and 9·4 months respectively. Six patients were alive beyond 5 years after TSH. Multivariable logistic regression analysis showed that failure to complete TSH was driven by two independent prognostic scenarios: three or more CLM in the future remnant liver (FRL) combined with age over 70 years predicted tumour progression after first-stage hepatectomy, and three or more CLM in the FRL combined with carcinomatosis at the time of first-stage hepatectomy predicted the development of additional FRL metastases after PVE/PVL.
  
  
  CONCLUSIONS
  A therapeutic strategy using TSH provided acceptable long-term survival with no postoperative mortality. Further efforts are needed to increase the number of patients who undergo TSH successfully.
authors.affiliation: Centre de Chirurgie Viscérale et de Transplantation, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
authors.forename: M
authors.initials: M
authors.lastname: Narita
authors.forename: E
authors.initials: E
authors.lastname: Oussoultzoglou
authors.forename: D
authors.initials: D
authors.lastname: Jaeck
authors.forename: P
authors.initials: P
authors.lastname: Fuchschuber
authors.forename: E
authors.initials: E
authors.lastname: Rosso
authors.forename: P
authors.initials: P
authors.lastname: Pessaux
authors.forename: E
authors.initials: E
authors.lastname: Marzano
authors.forename: P
authors.initials: P
authors.lastname: Bachellier
mesh_terms: D000328:Adult; D000368:Aged; D017024:Chemotherapy, Adjuvant; D002985:Clinical Protocols; D015179:Colorectal Neoplasms; D004621:Embolization, Therapeutic / Q000379:methods / Q000401:mortality; D005260:Female; D006498:Hepatectomy / Q000379:methods* / Q000401:mortality; D006801:Humans; D007430:Intraoperative Care / Q000379:methods / Q000401:mortality; D008113:Liver Neoplasms / Q000401:mortality / Q000556:secondary / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D011169:Portal Vein; D016896:Treatment Outcome